Key Takeaways:
- Pharmora takeover Apex Healthcare advances as Pharmora Investment Holdings raises its holding to 94.94% (685.95 million shares).
- The unconditional voluntary takeover offer remains open until 5pm on 5 January 2026, allowing further acceptances.
- Pharmora is an SPV jointly held by Quadria Capital Fund III Holdings and Dr Kee Kirk Chin, Apex’s major shareholder, chairman and CEO.
Pharmora Investment Holdings Pte Ltd has increased its effective interest in Apex Healthcare Bhd to 94.94 per cent, the company announced in a Bursa Malaysia filing on Tuesday. The stake represents 685.95 million Apex shares, acquired under an unconditional voluntary takeover offer that remains open to acceptances until 5pm on Monday, 5 January 2026.
Pharmora takeover Apex Healthcare: stake reaches near-total ownership
The move follows earlier purchases that had already given Pharmora a dominant position. As at 22 December 2025, Pharmora held 659.05 million shares, equal to 91.22 per cent of Apex. On 23 December it bought a further 3.08 million shares on the open market, lifting its effective interest to 91.65 per cent, before the most recent acceptance round pushed the holding to just under 95 per cent.
Pharmora is a special-purpose vehicle jointly held by Quadria Capital Fund III Holdings Pte Ltd and Dr Kee Kirk Chin, who is Apex Healthcare’s major shareholder, chairman and chief executive officer. The company said the offer remains unconditional and will continue to accept acceptances until the specified closing time on 5 January.
With a holding approaching full ownership, Pharmora now controls the vast majority of Apex’s issued shares. That position typically gives a bidder significant flexibility to pursue strategic steps, including potential privatisation, restructuring or changes to board composition, depending on regulatory rules and the decisions of remaining minority shareholders.
Apex Healthcare is listed on Bursa Malaysia and operates in the pharmaceutical distribution and retail segment. The firm’s transfer into near-total private ownership could accelerate strategic decisions away from the public market’s short-term pressures. It may also allow the new owners to invest in operations, realign management priorities or pursue mergers and integrations in the healthcare sector.
Market participants will watch whether Pharmora makes further moves to acquire the remaining shares. Under Malaysian corporate practice, crossing certain thresholds can enable a bidder to initiate compulsory acquisition of outstanding shares or to apply for delisting, subject to approvals and statutory requirements.
For minority shareholders, the current open offer period provides an opportunity to accept the offer if they wish to exit, or to hold on in the expectation of a further approach. The announcement did not disclose the offer price in the filing posted to Bursa Malaysia, nor did it give an immediate timetable for any subsequent actions by Pharmora.
Industry analysts say the transaction highlights continued investor interest in Southeast Asia’s healthcare assets. Quadria Capital, which co-controls Pharmora, is known for investing in health-care companies across the region. Dr Kee’s involvement as a principal of both Apex and Pharmora underlines the transaction’s strategic nature and continuity of management intent.
As the acceptance window remains open until early January, final ownership may change further. Investors and regulators will assess the outcome for its implications on corporate governance, market liquidity and the broader healthcare sector in Malaysia.
